Creso Pharma beats 2.5m cannaQIX® lozenges sales milestone
Health & Biotech
Link copied to
Special Report: Creso Pharma has beaten a key sales milestone for its flagship hemp-derived supplement range.
Creso Pharma (ASX:CPH) has beaten its 2.5m lozenge global sales milestone for the cannaQIX® line of hemp oil derived food supplements.
That figure represents sales of over 100,000 packs sold since its launch in April 2018.
Revenue from the sale of cannaQIX® lozenges in 2019 was $1.2m.
“We are proud that cannaQIX® has reached this milestone,” Creso cofounder and CEO Dr Miri Halperin Wernli said.
“The cannaQIX® line is Creso Pharma’s hemp oil/vitamins and minerals-based food supplement, oral cosmetic and medical cannabis, which has been developed with a unique proprietary buccal delivery system.
“The products help manage stress and pain, and support better sleep. We are looking forward to upcoming launches together with our new partners in additional countries and continents such as South Africa and Latin America in 2020.”
The cannaQIX® supplement is currently available in Switzerland, UK, Australia, Brazil and New Zealand.
Creso Pharma developed cannaQIX® 10 to help manage stress and cannaQIX® 25 and 50 to help manage chronic pain.
The company produces the cannaQIX® range of products in Switzerland and has commercialised them in collaboration with several partners in Europe, Oceania and Latin America.
The products are being distributed through pharmacies and drug stores in Europe as well as through doctors and clinics in Oceania and Latin America.
Creso commercial director Jorge Wernli said Creso Pharma’s cannaQIX® hemp oil-derived products were produced in Good Manufacturing Practice (GMP)-certified facilities complying with local regulatory requirements.
“Creso Pharma has developed an attractive product portfolio responding to customer needs and complying with regulations,” he said.
“With our technological capabilities and international scientific and commercial partnerships, we are well-positioned to continue growing our portfolio of commercialised animal and human health products.”